Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers. The patent, licensed from The University of British Columbia, includes coverage for the method for treating cancers that express the protein clusterin using OGX-011, or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex. "Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011."

OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67 granted or issued U.S. and foreign patents, and approximately 140 pending U.S. and foreign patent applications worldwide. Composition of matter patents covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the U.S. and certain other jurisdictions. Additional patent applications covering all of these products, as well as other technologies, are pending in the U.S. and certain other countries. TRPM-2 is an historical name for clusterin, and survives in some of the earlier patent filings.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and c
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , November 27, 2014 ... revolutionising the management of tooth decay, today announces ... of its Calcivis® Caries Activity Imaging System. ... a sophisticated medical device and consumable combination designed ... caries (tooth decay). It involves a unique, proprietary ...
(Date:11/26/2014)... NOVEMBER 21, 2014 (PRWEB) November 26, 2014 ... health-oriented communications network, today announced the organization has won ... Rx Club Awards. Digitas Health LifeBrands was honored with ... four other PHCG agencies received eight Awards of Excellence. ... creative aspects of pharmaceutical advertising and promotion. The Awards ...
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industryā€¯ is a professional and in-depth research report ... Bifluoride information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/26/2014)... In keeping with the holiday spirit, ... last-minute Thanksgiving savings. The company is offering up a ... lines this holiday weekend as well as a photo ... Cyber Monday are right around the corner, and DNA ... customers and those looking to explore their ancestry, health, ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3
... 11 Telik, Inc.,(Nasdaq: TELK ) reported a net ... quarter ended June 30, 2008, compared with a net loss ... in 2007. The,$13.6 million net loss for the second quarter ... to auction rate securities, which,is reflected in interest and other ...
... Inc., administrator for the,HealthShares(TM) Indexes, a series of ... today announced the following,change effective on the opening ... (Frankfurt, Germany: BIO) will replace Speedel Holding AG ... Speedel,Holding AG is being acquired by Novartis AG ...
... Aug. 11 Informed Medical Communications,(IMC), a leading ... issued its position today on recent revisions,to the ... with the,PhRMA Code," noted Dr. Jaime Nguyen, Medical ... we have continually monitored,the compliance trends so that ...
Cached Biology Technology:Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index 2Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2
... S. Serianni is providing new insights that could have ... points out that biological compounds known as dicarbonyl sugars ... breakdown of the simple sugar, glucose. The formation of ... concentrations in the blood and plasma of diabetics are ...
... Dec. 12, 2012 Wake Forest Baptist Medical Center ... its academic and clinical research and discoveries into marketable ... enterprise, Wake Forest Innovations, is being led by Chief ... who is also President of the Piedmont Triad ...
... humans and 200 Asian elephants every year. One of the ... elephants into ranges away from humans, often into national parks. ... elephants raiding crops, breaking into homes and injuring or killing ... published Dec. 7 in PLOS ONE by the ...
Cached Biology News:Notre Dame research may have important implications for combating diabetes 2Wake Forest Baptist Medical Center Launches Wake Forest Innovations 2Wake Forest Baptist Medical Center Launches Wake Forest Innovations 3Relocating elephants fails to decrease human-wildlife conflict 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: